tradingkey.logo

Carlsmed Q4 revenue surges, driven by AI-enabled spine surgery solutions

ReutersFeb 25, 2026 9:16 PM


Overview

  • Medical technology firm's Q4 revenue grew 61% yr/yr

  • Company reported Q4 net loss of $8.6 mln

  • Company launched new cervical and bilateral fusion systems


Outlook

  • Carlsmed expects 2026 revenue between $70 mln and $75 mln


Result Drivers

  • REVENUE GROWTH - Carlsmed reported a 61% increase in Q4 revenue, driven by scaling of AI-enabled spine surgery solutions

  • GROSS MARGIN EXPANSION - Gross margin improved to 76.5% in Q4, reflecting operational efficiencies


Company press release: ID:nGNX482rTG


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Net Income

-$8.60 mln

Q4 Adjusted EBITDA

-$8.40 mln

Q4 Gross Margin

76.50%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Carlsmed Inc is $18.00, about 37.8% above its February 24 closing price of $13.06


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI